The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...

Drugmaker Daiichi Sankyo has risen the most in five months after its novel breast cancer treatment won U.S. approval, a ...

The planned bonds are expected to have a call option after 10 years. Fitch Ratings anticipates Dai-ichi Life's financial ...

Dai-ichi Life Insurance Co. lost about ¥140 billion ($890 million ... first half of the fiscal year and would be “more restrained” in the second half, the company’s president, Toshiaki Sumino, said in ...

It's the end of the road for the South San Francisco-based company, which became part of the Daiichi Sankyo in a $935 million deal in 2011 and since then has contributed two approved cancer ...

Dai ichi Life Insurance Company Ltd decreased its holdings in Amazon.com, Inc. (NASDAQ:AMZN) by 13.6% during the 3rd quarter, ...

Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual ...

Daiichi Sankyo has finalised the acquisition of intellectual property rights for gatipotuzumab, an anti-tumour-associated ...

Daiichi Sankyo to pay $132.5 million to acquire IP rights for anti-TAMUC1 antibody in DS-3939 from Glycotope: Tokyo Wednesday, January 15, 2025, 09:00 Hrs [IST] Daiichi Sankyo Com ...

Daiichi Sankyo (OTCPK ... It's also the second DXd antibody-drug conjugate, or ADC, approved based on the company's DXd ADC technology. Market applications for Datroway in breast cancer are ...

Japanese drugmaker Daiichi Sankyo announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property ...